Enveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates
The EVM401 Series comprises proprietary, non-hallucinogenic mescaline-derived compounds designed to promote neuroplasticity for the potential treatment of psychiatric and neurological disorders.The patent application,
Enveric got permission to protect special brain medicines it invented. This shows its work is real and harder for others to copy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.